Nuvectis Pharma Inc. (NVCT) News

Nuvectis Pharma Inc. (NVCT): $9.92

0.51 (+5.42%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter NVCT News Items

NVCT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

NVCT News Highlights

  • NVCT's 30 day story count now stands at 3.
  • Over the past 4 days, the trend for NVCT's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about NVCT are LEE and MD.

Latest NVCT News From Around the Web

Below are the latest news stories about NUVECTIS PHARMA INC that investors may wish to consider to help them evaluate NVCT as an investment opportunity.

Nuvectis Pharma Announces Collaboration with ENGOT and GOG Foundation to Conduct the NXP800 Phase 1b Clinical Trial in ARID1A-Mutated Ovarian Carcinoma in Europe and in the United States

Dr. Susana Banerjee (The Royal Marsden NHS Foundation Trust, UK), will be the ENGOT and Global Clinical Trial Lead

GlobeNewswire | January 4, 2023

Is Nuvectis Pharma, Inc. (NASDAQ:NVCT) Trading At A 33% Discount?

How far off is Nuvectis Pharma, Inc. ( NASDAQ:NVCT ) from its intrinsic value? Using the most recent financial data...

Yahoo | December 31, 2022

NVCT stock gains on FDA Fast Track status for cancer candidate (NASDAQ:NVCT)

Oncology-focused biotech Nuvectis Pharma (NVCT) announced Thursday that the FDA granted Fast Track Designation to the product candidate NXP800 for the treatment of a certain form of…

Seeking Alpha | December 1, 2022

FDA Grants Fast Track Designation to Nuvectis Pharma's NXP800 for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma

Fort Lee, NJ, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that the U.S. Food and Drug Administration (the “FDA”) has granted Fast Track Designation to NXP800 for the treatment of platinum-resistant, ARID1A-mutated ovarian carcinoma. “We are very pleased with the

Yahoo | December 1, 2022

Companies Like Nuvectis Pharma (NASDAQ:NVCT) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | November 30, 2022

Nuvectis Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Highlights

FORT LEE, N.J., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial results for the third quarter of 2022 and provided an update on recent business progress.

GlobeNewswire | November 8, 2022

Nuvectis Phrama Announces Two Upcoming Poster Presentations at the 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

FORT LEE, N.J., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the publication of abstracts for two posters that will be presented at the upcoming 34th EORTC-NCI-AACR Symposium on molecular targets and cancer therapeutics (“2022 ENA”), taking place from October 26t

Yahoo | October 18, 2022

Nuvectis Pharma, Inc. (NASDAQ:NVCT) insiders seem bullish, own 58% and have been buying more recently

To get a sense of who is truly in control of Nuvectis Pharma, Inc. ( NASDAQ:NVCT ), it is important to understand the...

Yahoo | October 17, 2022

Nuvectis Pharma, Inc. to Present at the Roth Inaugural Healthcare Opportunities Conference

FORT LEE, N.J., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. ("Nuvectis", "Company"), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that the Company’s management team will participate at the Roth Inaugural Healthcare Opportunities Conference. EventRoth Inaugural Healthcare Opportunities ConferenceDateOctober 6, 2022Time8:15 a.m. ETLocationNew York About

Yahoo | October 3, 2022

Nuvectis Pharma (NVCT) Investor Presentation - Slideshow (NASDAQ:NVCT)

The following slide deck was published by Nuvectis Pharma, Inc.

Seeking Alpha | September 29, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 1.658 seconds.